Circio Holding ASA - Share Issue/Capital Change 2026

Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders

Oslo, 29 January 2026: Reference is made to the stock exchange announcements

by Circio Holding ASA (the "Company") on 15 January 2026, regarding the

commencement of the subscription period for the rights issue (the "Rights

Issue") and the receipt of subscription rights in the Rights Issue by certain

primary insiders and close associates.

Certain primary insiders and close associates have on the dates as stated

below, exercised subscription rights and subscribed for shares:

* Biopharma Drug Licensing Group, SL, a closely associated company of Lubor

Gaal, CFO of the Company, has on 28 January 2026 exercised 65,164

subscription rights, thus entitling the company to be allocated 65,164 offer

shares in the Rights Issue. In addition, Biopharma Drug Licensing Group has

subscribed for 204,836 offer shares without subscription rights, thereby

subscribing for a total of 270,000 offer shares at the subscription price in

the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a

corresponding number in warrants without additional consideration, subject

to allocation by the board of directors and the completion of the Rights

Issue.

Please see the attached notifications of trade for information regarding the

subscription rights exercised by primary insiders in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683 34 3811

AI assistant